On Nov 19, major Wall Street analysts update their ratings for $Aclaris Therapeutics (ACRS.US)$, with price targets ranging from $3 to $13.
Jefferies analyst Roger Song upgrades to a buy rating, and adjusts the target price from $1 to $7.
Stifel analyst Alex Thompson CFA maintains with a hold rating, and maintains the target price at $3.
BTIG analyst Julian Harrison upgrades to a buy rating, and sets the target price at $8.
Piper Sandler analyst Christopher Raymond upgrades to a buy rating, and adjusts the target price from $2 to $13.
Leerink Partners analyst Thomas Smith upgrades to a buy rating, and adjusts the target price from $2 to $7.
Furthermore, according to the comprehensive report, the opinions of $Aclaris Therapeutics (ACRS.US)$'s main analysts recently are as follows:
BSI-045B, being the first anti-TSLP demonstrating clinical proof of concept in atopic dermatitis, is considered to be underpinned by a distinct binding profile. Further development in a placebo-controlled study is supported for additional substantiation in atopic dermatitis and potentially other areas. Should these studies prove successful, BSI-045B could emerge as a pioneer in the congested atopic dermatitis market with a unique mechanism of action that potentially improves both efficacy and safety.
Aclaris Therapeutics has taken a significant step by acquiring the complete ex-China rights to an anti-TSLP humanized mAb and anti-TSLP/IL4R bispecific mAb. This acquisition is highlighted by the remarkable potency of BSI-045B, which has demonstrated up to 71-times greater efficacy versus tezepelumab, and up to nine times higher potency compared to other anti-TSLP therapies currently under development. Impressively, early Phase 2a open-label data suggests that BSI-045B could become a preferred early-line treatment for atopic dermatitis.
Here are the latest investment ratings and price targets for $Aclaris Therapeutics (ACRS.US)$ from 5 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
美东时间11月19日，多家华尔街大行更新了$Aclaris Therapeutics (ACRS.US)$的评级，目标价介于3美元至13美元。
富瑞集团分析师Roger Song上调至买入评级，并将目标价从1美元上调至7美元。
斯迪富分析师Alex Thompson CFA维持持有评级，维持目标价3美元。
BTIG分析师Julian Harrison上调至买入评级，目标价8美元。
派杰投资分析师Christopher Raymond上调至买入评级，并将目标价从2美元上调至13美元。
Leerink Partners分析师Thomas Smith上调至买入评级，并将目标价从2美元上调至7美元。
此外，综合报道，$Aclaris Therapeutics (ACRS.US)$近期主要分析师观点如下：
BSI-450亿，作为第一个在特应性皮炎中展示临床证明概念的抗TSLP药物，被认为具有独特的结合特征。为了在特应性皮炎及其他潜在领域提供更多支持，进一步在安慰剂对照研究中的开发已得到支持。如果这些研究证明成功，BSI-450亿可能在拥挤的特应性皮炎市场中成为一款具有独特作用机制的先锋，可能提高疗效和安全性。
aclaris therapeutics通过收购抗TSLP人源化单克隆抗体和抗TSLP/IL4R双特异性单克隆抗体的全部中国以外权利，迈出了重要一步。这次收购的亮点在于BSI-450亿的卓越效力，其与tezepelumab相比表现出最高达71倍的效果，与目前正在开发的其他抗TSLP疗法相比，提高了近九倍的效力。令人印象深刻的是，早期的2a期开放标签数据表明，BSI-450亿可能成为特应性皮炎的优选早期治疗。
以下为今日5位分析师对$Aclaris Therapeutics (ACRS.US)$的最新投资评级及目标价：
提示:
TipRanks为独立第三方，提供金融分析师的分析数据，并计算分析师推荐的平均回报率和胜率。提供的信息并非投资建议，仅供参考。本文不对评级数据和报告的完整性与准确性做出认可、声明或保证。
TipRanks提供每位分析师的星级，分析师星级代表分析师所有推荐的过往表现，通过分析师的总胜率和平均回报率综合计算得出，星星越多，则该分析师过往表现越优异，最高为5颗星。
分析师总胜率为近一年分析师的评级成功次数占总评级次数的比率。评级的成功与否，取决于TipRanks的虚拟投资组合是否从该股票中产生正回报。
总平均回报率为基于分析师的初始评级创建虚拟投资组合，并根据评级变化对组合进行调整，在近一年中该投资组合所获得的回报率。
